According to the relevant provisions of the 'Environmental Impact Assessment Law of the People's Republic of China' and 'Measures for Public Participation in Environmental Impact Assessment' (Ministry of Ecology and Environment Order No.

The evaluation will be publicized for the first time, so that the public can understand the project situation, and at the same time understand the public's suggestions and opinions on the environmental protection of the project construction, and accept the supervision of the whole society.

About SINOVAC

Sinovac Biotech Ltd. (Sinovac Biotech Ltd., SINOVAC Kexing) is a leading biological high-tech enterprise in China. With the mission of 'providing vaccines for human elimination of diseases', it is committed to the research of human vaccines and related products, Development, production and sales, providing services for global disease prevention and control.

The vaccines developed by SINOVAC mainly include vaccines against viral hepatitis, influenza, pneumonia, polio, chickenpox, mumps and other common infectious diseases, as well as against SARS, H5N1 avian influenza, H1N1 influenza, EV71 hand, foot and mouth disease, new Vaccines for new and sudden infectious diseases such as coronavirus infection.

The company's existing 4 vaccines have passed the pre-certification of the World Health Organization (inactivated hepatitis A vaccine, inactivated polio vaccine of Sabin strain, live attenuated varicella vaccine) or included in the emergency use list (inactivated vaccine of new coronavirus), the quality of the vaccine The management system has been recognized by international organizations and multinational drug regulatory authorities.

SINOVAC is constantly exploring opportunities in the international market, and has exported vaccines to dozens of countries and international organizations.

Contact:

Tel: +86-10-8289-0088

Fax: +86-10-6296-6910

Email: sinovac@sinovac.com

(C) 2023 Electronic News Publishing, source ENP Newswire